557 / 1068
5. HDR-EBT – Definitive option
Herbert study (presented at ESTRO 2016)
- Dose-finding feasibility study of EBRT + HDR-EBT
boost for patients unfit for surgery
- Rectal adenocarcinoma < 15 cm, < 2/3 of
circumference, cT2-4 N0-1 M0-1
- Life expectancy ≥ 6 months
Marijnen C., Rijkmans E. LUMC, Leiden, The Netherlands.
Presented at ESTRO 2016